OakChart

Celldex Therapeutics Inc

CLDXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:04 AM ET

30.76+0.11 (0.36%)
2026-11-11 16:05 CET
Market cap
2,407.41 USD m
Revenue, TTM
0.16 USD m
Net income, TTM
-309.06 USD m
Free cash flow, TTM
-259.74 USD m
EPS diluted, TTM
-4.31
P/E
-
Compare

Price

CLDX against its 20, 50 and 200-day averages
2050200beat
30.0035.0040.0045.006.4M12.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLDXclose 30.7620-day 29.6450-day 32.42200-day 32.8030.76

31.9% under 45.14 on 12 Aug 2026. Last 15 sessions, 14.0% high to low

Profile

CLDX
52-week range, 38% of the way up
22.1045.14

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

IndexRUT
Employees198
IPOMay 15, 1986
Beta1.02
ATR, 14d1.48
Rel volume0.10
Short float13.08%
Insider own3.32%
Inst own105.38%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.42B
Enterprise Value1.78B
Income-309.06M
Sales0.16M
Book/sh8.27
Cash/sh8.21
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees198
IPOMay 15, 1986

Ratios

P/E-
Forward P/E-
PEG-
P/S15100.31
P/B3.72
P/C3.75
P/FCF-
EV/EBITDA-
EV/Sales11131.88
Quick Ratio10.97
Current Ratio10.97
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.31
EPS next Y-3.99
EPS next Q-1.01
EPS this Y-4.72%
EPS next Y2.29%
EPS next 5Y5.37%
EPS past 3/5Y-17.59% -14.07%
Sales past 3/5Y-13.13% -26.93%
EPS Y/Y TTM-27.48%
Sales Y/Y TTM-93.92%
EPS Q/Q4.69%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.5.56% -100.00%

Ownership

Insider Own3.32%
Insider Trans0.00%
Inst Own105.38%
Inst Trans25.01%
ROA-45.12%
ROE-49.54%
ROIC-46.98%
Gross Margin-2263.29%
Oper. Margin-211684.81%
Profit Margin-195608.86%
SMA203.78%
SMA50-5.12%
SMA200-6.23%
Trades-

Technical

Shs Outstand78.53M
Shs Float75.94M
Short Float13.08%
Short Ratio7.35
Short Interest9.94M
52W High45.14 -31.86%
52W Low22.10 39.19%
Volatility6.74% 5.03%
ATR (14)1.48
RSI (14)51.15
Beta1.02
Rel Volume0.10
Avg Volume1.35M
Volume18,260

Performance

Perf Week2.77%
Perf Month8.88%
Perf Quarter-27.81%
Perf Half Y-5.38%
Perf YTD13.25%
Perf Year26.22%
Perf 3Y14.18%
Perf 5Y-30.72%
Perf 10Y-52.53%
Recom1.20
Target Price64.00
Prev Close30.65
Price30.76
Change %0.36%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 22, 2026ReiteratedHH.C. WainwrightBuy$42 → $64+108.1%
Apr 20, 2026UpgradeBBarclaysUnderweight → Overweight$45+46.3%
Mar 23, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$44+43.0%
Oct 21, 2025InitiatedMMizuhoOutperform$48+56.0%
Oct 13, 2025InitiatedBBarclaysUnderweight$25-18.7%
Apr 28, 2025InitiatedCCanaccord GenuityBuy$64+108.1%
Mar 20, 2025InitiatedMMorgan StanleyOverweight$46+49.5%
Feb 13, 2025InitiatedUUBSBuy$44+43.0%
Oct 07, 2024InitiatedCCitigroupBuy$70+127.6%
Sep 30, 2024InitiatedGGoldmanNeutral$45+46.3%

Peers

Mkt cap
TickerCompanyMkt cap
JSPRJasper Therapeutics Inc15.78M
SEPNSepterna Inc2.34B
EVMNEvommune Inc303.11M
INCYIncyte Corp24.48B
NVSNovartis AG ADR292.23B
REGNRegeneron Pharmaceuticals Inc93.50B
ARQTArcutis Biotherapeutics Inc3.58B
IMVTImmunovant Inc7.51B
SNYSanofi ADR113.47B
UPBUpstream Bio Inc186.50M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Martin Samuel BatesSVP AND CFOJan 02 '26Option Exercise10.384,81750,00032,942Jan 06 04:23 PM
PEPIN RONALDSR. VP & CBODec 15 '25Option Exercise5.4719,333105,71420,097Dec 17 04:06 PM
Jimenez Freddy A.SVP & GENERAL COUNSELDec 04 '25Sale29.094,166121,21030,796Dec 08 04:20 PM
FREDDY A JIMENEZOfficerDec 04 '25Proposed Sale29.104,166121,210Dec 04 04:04 PM
Wright Richard M.Former OfficerNov 13 '25Option Exercise14.0649,298692,91370,131Nov 17 04:17 PM
Wright Richard M.Former OfficerNov 13 '25Sale24.0049,2981,183,17720,833Nov 17 04:17 PM
RICHARD M WRIGHTOfficerNov 13 '25Proposed Sale24.0049,2981,183,177Nov 13 04:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-

News

latest 14 of 202
  • Guggenheim reiterates this biotech stock as a top pick (Investing.com)
  • Celldex: Q3 Earnings Snapshot (Associated Press) -5.55% +5.66%
  • Celldex Reports Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
  • Celldex to Present at Upcoming Investor Conferences (GlobeNewswire)
  • MARKETS LIVE: Futures slip ahead of Meta address (Proactive) -7.13%
  • Loading…
  • CLDX Stock Slumps 11% This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns Misplaced (Stocktwits) -11.56%
  • Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials (InvestorsHub)
  • Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints (GlobeNewswire)
  • Celldex to Present at Upcoming Investor Conference (GlobeNewswire)
  • Celldex: Q2 Earnings Snapshot (Associated Press)
  • Celldex Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
  • Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study (BioPharma Dive)
  • CLDX Stock Down 10% After-Hours Whats Driving The Selloff? (Stocktwits)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.960-1.017-0.9600.000.7213
2026Q22026-08-06-0.940-1.057-0.9440.020.7314
2026Q12026-05-07-1.180-1.150-1.1820.020.8013
2025Q42026-02-25-1.220-1.022-1.2230.101.3215
2025Q32025-11-10-1.010-0.900-1.0090.000.9915
2025Q22025-08-07-0.850-0.856-0.8530.731.0314
2025Q12025-05-08-0.810-0.755-0.8100.701.0013
2024Q42025-02-27-0.710-0.737-0.7101.181.0211
2024Q32024-11-06-0.640-0.673-0.6353.190.8411
2024Q22024-08-08-0.540-0.588-0.5432.500.859
2024Q12024-05-06-0.560-0.693-0.5570.200.817
2023Q42024-02-26-0.830-0.734-0.8324.131.448
2023Q32023-11-02-0.810-0.680-0.8101.520.587
2023Q22023-08-08-0.650-0.658-0.6460.270.536
2023Q12023-05-04-0.620-0.622-0.6220.970.415
2022Q42023-02-28-0.560-0.590-0.5621.610.266

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.510-3.860-3.5073.573.15
2020FY-2.020-1.773-2.0177.424.20
2021FY-1.640-1.640-1.6454.655.34
2022FY-2.400-2.382-2.3962.360.99
2023FY-2.920-2.804-2.9196.884.11
2024FY-2.450-2.475-2.4527.026.86
2025FY-3.900-3.710-3.9001.552.71
2026FY--4.084--1.27
2027FY--3.991--6.48
2028FY--3.305--105.75
2029FY--0.315--452.91
2030FY-3.917--937.83

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0610221.500.006.46
2026Q4S2026-11-0510001.220.004.50
2026Q4S2026-10-2111001.200.004.50
2026Q4S2026-09-2211411.200.004.50
2026Q4S2026-09-0411411.200.004.46
2026Q4S2026-08-0712421.160.004.46
2026Q4S2026-07-2412011.020.003.00
2026Q4S2026-07-2212001.020.003.00
2026Q4S2026-06-0912501.020.003.00
2026Q4S2026-05-1211501.110.003.00
2026Q4S2026-05-0811511.110.003.00
2026Q4S2026-02-2711120.820.003.00
2026Q4S2026-02-2610120.900.003.00
2026Q4S2026-02-249000.670.001.50

Estimate history

EPS, annual-10.8-14.478-3.507-2.017-1.645-2.396-2.919-2.452-3.896-4.3115
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.635-0.71-0.81-0.853-1.009-1.223-1.182-0.944-0.962
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual12.7439.5383.5737.4184.6512.3576.8837.021.5450.16
Period201720182019202020212022202320242025TTM
Sales, quarterly3.1911.1750.6950.7300.1210.0150.0220
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual9.23511.95816.97239.60446.7347.20155.88366.37566.54978.534
Period201720182019202020212022202320242025MRQ
Shares, quarterly66.34466.37566.38466.39466.44766.54966.56978.578.534
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.161.547.026.882.364.657.423.579.54
Cost of Goods Sold Incl. D&A3.733.383.183.011.403.07---
Gross Profit-3.58-1.833.843.880.961.58---
Selling, General and Administrative Excl. Other330.89285.53198.92145.92108.0570.7354.9953.2482.14
Research and Development279.55241.69160.37115.0080.8650.2440.5337.8166.45
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-334.46-287.37-195.08-142.04-107.10-69.15-49.57-54.52-76.40
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.0012.508.142.1013.780.5180.03
Net Income Before Taxes-309.06-258.76-157.86-141.43-112.33-70.74-60.95-50.88-151.95
Income Taxes0.000.000.000.000.00-0.23-1.170.00-0.77
Consolidated Net Income-309.06-258.76-157.86-141.43-112.33-70.51-59.78-50.88-151.18
Net Income From Continuing Operations-309.06-258.76-157.86-141.43-112.33-70.51-59.78-50.88-151.18
Net Income-309.06-258.76-157.86-141.43-112.33-70.51-59.78-50.88-151.18
EPS (Recurring)-3.94-3.90-2.45-2.74-2.27-1.61-1.69-3.48-9.11
EPS (Basic, Before Extraordinaries)-4.31-3.90-2.45-2.92-2.40-1.64-2.02-3.51-14.48
EPS (Diluted)-4.31-3.90-2.45-2.92-2.40-1.64-2.02-3.51-14.48
EBITDA-330.73-283.99-191.90-139.03-105.70-66.08-47.57-49.67-72.60
Non-Operating Income (Expense)25.4028.6137.2213.112.910.512.414.154.49
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense36.8136.2234.2423.8915.618.952.864.556.38
Price To Sales Ratio16,108.801,167.65231.80279.16886.63356.1670.009.053.25
Gross Margin-2,263.29-118.7754.7456.3040.6034.04---
Operating Margin-211,684.81-18,599.81-2,778.89-2,063.66-4,543.74-1,486.73-668.27-1,526.03-801.05
Net Margin-195,608.86-16,748.03-2,248.76-2,054.76-4,765.59-1,516.04-805.88-1,423.96-1,585.07
Shares Outstanding78.5366.5566.3755.8847.2046.7339.6016.9711.96
Market Capitalization2,407.412,407.411,676.522,168.972,099.241,803.09693.2237.2735.50

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.020.010.120.000.730.691.18
Cost of Goods Sold Incl. D&A1.160.900.850.820.820.870.870.82
Gross Profit-1.16-0.88-0.84-0.69-0.82-0.14-0.170.36
Selling, General and Administrative Excl. Other81.0979.7483.6086.4672.7963.7162.5756.38
Research and Development66.2566.6472.1574.5262.1153.3251.7546.12
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-82.25-80.62-84.44-87.15-73.62-63.86-62.74-56.03
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-75.56-73.50-78.69-81.32-67.04-56.60-53.80-47.09
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-75.56-73.50-78.69-81.32-67.04-56.60-53.80-47.09
Net Income From Continuing Operations-75.56-73.50-78.69-81.32-67.04-56.60-53.80-47.09
Net Income-75.56-73.50-78.69-81.32-67.04-56.60-53.80-47.09
EPS (Recurring)-0.96-0.94-1.18-1.22-1.01-0.85-0.81-0.71
EPS (Basic, Before Extraordinaries)-0.96-0.94-1.18-1.22-1.01-0.85-0.81-0.71
EPS (Diluted)-0.96-0.94-1.18-1.22-1.01-0.85-0.81-0.71
EBITDA-81.09-79.72-83.58-86.34-72.79-62.98-61.87-55.21
Non-Operating Income (Expense)6.697.125.755.846.577.268.948.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.978.418.528.918.809.199.329.78
Price To Sales Ratio16,108.8018,331.812,438.191,168.07660.88233.31159.39238.85
Gross Margin--4,000.00-5,593.33-574.38--19.59-24.7530.30
Operating Margin--366,468.18-562,900.00-72,027.27--8,747.53-9,027.19-4,768.26
Net Margin--334,104.55-524,566.67-67,204.13--7,753.42-7,740.43-4,007.83
Shares Outstanding78.5378.5066.5766.5566.4566.3966.3866.37
Market Capitalization2,407.412,920.692,111.481,804.771,717.941,351.121,204.871,676.52

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments514.17719.18421.70304.15406.95194.2264.1893.92139.13
Short Term Receivables6.426.804.531.151.472.001.223.262.18
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets14.0821.185.4712.392.421.621.301.903.45
Total Current Assets534.66747.16431.69317.69410.84197.8466.7099.08144.76
Net Property, Plant & Equipment7.778.246.647.756.527.267.506.1110.37
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets27.1927.1927.1927.1927.1930.6948.6948.69158.57
Other Assets13.369.750.110.100.100.040.041.931.93
Total Assets582.98792.34465.63352.74444.65235.84122.93155.81315.62
Short Term Debt Incl. Current Port. of LT Debt1.551.451.611.451.751.331.940.000.00
Accounts Payable1.183.273.493.341.231.051.171.071.72
Other Current Liabilities48.2634.7826.0213.8213.5511.838.5311.5326.02
Total Current Liabilities50.9939.5031.1218.6116.5314.2111.6412.6027.74
Long Term Debt0.782.360.932.591.302.151.710.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities4.043.474.405.337.3510.1215.5519.1551.52
Total Liabilities55.8245.3436.4626.5325.1826.4828.9131.7579.25
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity527.16747.00429.17326.20419.48209.3694.03124.06236.37
Total Shareholders Equity527.16747.00429.17326.20419.48209.3694.03124.06236.37
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity527.16747.00429.17326.20419.48209.3694.03124.06236.37
Total Liabilities & Stockholders Equity582.98792.34465.63352.74444.65235.84122.93155.81315.62
Book Value Per Share7.9211.257.686.918.985.295.5410.3825.60
Tangible Book Value Per Share7.5110.847.196.338.394.512.676.308.42
Full-Time Employees198186160148134125130137197
Price to Book Ratio3.712.137.606.084.303.310.400.291.71
Return on Assets-37.63-25.10-34.56-28.17-20.72-33.32-36.51-64.14-26.62
Return on Equity-40.62-26.84-37.45-30.13-22.43-39.41-46.66-83.89-37.08
Return on Invested Capital-49.01-21.07-32.88-34.16-16.76-28.26-53.14-121.86-39.36
Quick Ratio10.4918.9113.8717.0724.8613.935.737.865.22
Current Ratio10.4918.9113.8717.0724.8613.935.737.865.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-309.06-258.76-157.86-141.43-112.33-70.51-59.78-50.88-151.18
Depreciation3.733.383.183.012.903.073.934.863.80
Other Funds (Non Cash)32.8730.3718.5117.679.607.5915.753.9387.52
Funds from Operations-272.46-225.00-136.18-120.75-99.83-59.85-40.10-42.09-59.86
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital20.4914.06-21.6013.46-3.90-1.05-0.30-4.32-15.37
Cash from Operating Activities-251.97-210.94-157.78-107.29-103.73-60.91-40.40-46.41-75.23
Capital Expenditures-7.77-2.71-1.92-1.82-1.83-1.25-1.55-0.73-0.81
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.070.030.060.020.34
Purchase or Sale of Investments-76.79211.79-288.21-103.9691.70-214.93-96.7217.7930.29
Purchase of Investments-579.46-384.50-789.92-424.56-188.97-389.88-220.32-95.38-171.18
Sale Or Maturity of Investments502.67596.29501.71320.60280.67174.95123.60113.17201.47
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-84.56209.07-290.13-105.7889.94-216.16-98.2217.0829.82
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock327.452.39441.45218.464.08272.37171.2316.2629.44
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock327.452.39441.45218.464.08272.37171.2316.2629.44
Proceedsfrom Stock Options323.830.00432.30216.220.00269.89170.7916.2529.02
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities327.452.39441.45218.464.08272.37171.2316.2629.44
Net Change in Cash-9.090.52-6.465.38-9.71-4.6932.60-13.08-15.98
Free Cash Flow-259.74-213.66-159.70-109.11-105.56-62.16-41.96-47.15-76.05
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments644.82711.29446.76514.17577.22624.14
Short Term Receivables5.866.534.936.426.096.29
Inventories0.000.000.000.000.000.00
Other Current Assets13.067.117.5314.0821.0317.98
Total Current Assets663.74724.93459.22534.66604.34648.40
Net Property, Plant & Equipment20.9214.799.417.777.557.51
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets27.1927.1927.1927.1927.1927.19
Other Assets9.6915.4315.4313.369.369.30
Total Assets721.53782.35511.25582.98648.44692.41
Short Term Debt Incl. Current Port. of LT Debt1.441.561.471.551.551.54
Accounts Payable11.2414.6810.361.184.272.07
Other Current Liabilities47.8445.0939.6548.2640.6529.35
Total Current Liabilities60.5261.3351.4750.9946.4732.96
Long Term Debt8.433.350.440.781.071.50
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.113.113.114.042.542.54
Total Liabilities72.0667.7855.0355.8250.0837.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity649.47714.56456.23527.16598.36655.41
Total Shareholders Equity649.47714.56456.23527.16598.36655.41
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity649.47714.56456.23527.16598.36655.41
Total Liabilities & Stockholders Equity721.53782.35511.25582.98648.44692.41
Book Value Per Share8.279.106.857.929.019.87
Tangible Book Value Per Share7.928.766.447.518.609.46
Full-Time Employees---198--
Price to Book Ratio3.715.434.003.022.621.92
Return on Assets-45.12-40.76-45.36-37.63-30.51-25.96
Return on Equity-49.54-43.88-48.94-40.62-32.44-27.17
Return on Invested Capital-11.48-10.24-17.23-15.40-11.18-8.62
Quick Ratio10.9711.828.9210.4913.0119.67
Current Ratio10.9711.828.9210.4913.0119.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-75.56-73.50-78.69-81.32-67.04-56.60
Depreciation1.160.900.850.820.820.87
Other Funds (Non Cash)10.236.717.908.037.797.50
Funds from Operations-64.16-65.89-69.94-72.47-58.43-48.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.878.484.358.539.804.22
Cash from Operating Activities-65.03-57.41-65.59-63.94-48.63-44.01
Capital Expenditures-1.67-3.18-1.64-1.28-0.44-0.73
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments45.09-252.3473.7656.7161.2950.58
Purchase of Investments-62.21-402.85-59.61-54.79-55.63-122.26
Sale Or Maturity of Investments107.29150.51133.37111.50116.92172.84
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities43.42-255.5272.1255.4260.8549.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.11324.660.331.350.770.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.11324.660.331.350.770.06
Proceedsfrom Stock Options0.00323.830.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.11324.660.331.350.770.06
Net Change in Cash-20.5011.726.86-7.1712.995.91
Free Cash Flow-66.70-60.59-67.23-65.22-49.07-44.73

Revenue breakdown

Grant2024: 7.01M 2025: 1.45M
Service2024: 13.00K 2025: 97.00K
United States2024: 7.02M 2025: 1.55M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.08%9.9M75.9M1.34M
2026-10-1512.64%9.6M75.9M1.35M
2026-09-3014.50%11.0M75.9M1.22M
2026-09-1511.79%9.0M75.9M1.01M
2026-08-3111.38%8.6M75.9M1.03M
2026-08-149.97%7.6M75.9M1.02M
2026-07-319.99%7.6M76.3M984.88K
2026-07-1510.05%7.7M76.3M949.45K
2026-06-3010.15%7.7M76.3M1.06M
2026-06-159.57%7.3M76.3M942.17K
2026-05-299.37%7.1M76.3M963.68K
2026-05-159.35%7.1M76.3M1.04M
2026-04-309.97%7.6M76.3M1.05M
2026-04-1510.90%8.3M76.2M992.90K
2026-03-3114.04%9.1M64.7M882.04K
2026-03-1314.29%9.2M64.7M805.76K
2026-02-2713.93%9.0M64.7M787.29K
2026-02-1314.22%9.2M64.6M714.14K
2026-01-3014.31%9.2M64.6M774.89K
2026-01-1514.00%9.0M64.6M806.35K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0013.5018.400.006.0930.000.000.968-0.0550.003
call20.008.5013.408.514.17523.000.000.847-0.2420.012
call21.007.6012.500.004.0290.000.000.834-0.2360.012
call22.006.6011.500.003.7300.000.000.821-0.2290.013
call23.005.6010.400.003.4420.000.000.805-0.2220.013
call24.004.609.400.003.1640.000.000.788-0.2130.014
call25.003.608.4018.052.8945.000.000.769-0.2040.015
call26.002.657.5018.052.63119.000.000.731-0.2410.016
call27.001.656.501.852.3711.000.000.703-0.2390.017
call28.001.005.503.602.11761.000.000.672-0.2360.018
call29.000.205.001.082.1851070.000.633-0.2390.018
call30.000.504.901.812.4401930.000.597-0.2330.019
call31.000.004.900.562.56528.000.000.576-0.2670.019
call32.000.054.900.752.77321.000.000.547-0.2780.019
call33.000.001.501.051.2054320.000.414-0.1380.019
call34.000.002.952.651.37050.000.000.368-0.1390.018
call35.000.002.550.381.5506230.000.341-0.1520.018
call36.000.004.9014.401.63453.000.000.322-0.1510.018
call37.000.004.901.051.75936.000.000.307-0.1590.018
call38.000.002.750.551.51060.000.000.229-0.1180.015
call39.000.004.900.051.61358.000.000.219-0.1230.015
call40.000.004.900.101.71163.000.000.210-0.1270.014
call41.000.004.909.001.80469.000.000.203-0.1310.014
call42.000.004.902.441.89451.000.000.196-0.1350.014
call43.000.004.909.001.98038.000.000.190-0.1380.014
call44.000.004.909.502.06216.000.000.185-0.1410.013
call45.000.000.600.052.1412,1630.000.180-0.1440.013
call46.000.004.900.102.21862.000.000.176-0.1470.013
call47.000.004.900.352.09034.000.000.134-0.1210.011
call48.000.004.900.352.36312.000.000.168-0.1520.013
call49.000.004.900.752.4328.000.000.165-0.1550.012
call50.000.004.001.552.4991,0450.000.162-0.1570.012
call55.000.004.900.952.61915.000.000.114-0.1350.009
call60.000.004.902.003.07523.000.000.140-0.1760.011
call65.000.004.900.503.1013,1990.000.101-0.1470.009
put15.000.000.200.302.67916.000.00-0.032-0.0490.004
put20.000.004.902.203.80811.000.00-0.153-0.2400.012
put21.000.004.902.003.52311.000.00-0.166-0.2340.012
put22.000.002.953.103.2481590.00-0.180-0.2270.013
put23.000.002.952.652.9841.000.00-0.195-0.2190.013
put24.000.002.952.802.7282.000.00-0.212-0.2110.014
put25.000.002.000.401.56413.000.00-0.177-0.1030.013
put26.000.002.750.152.7081620.00-0.269-0.2380.016
put27.000.004.901.401.5625.000.00-0.265-0.1300.016
put28.000.003.208.502.3011.000.00-0.326-0.2200.018
put29.000.004.901.302.44630.000.00-0.361-0.2370.018
put30.000.003.700.802.1631,1270.00-0.399-0.2280.019
put31.000.004.902.652.5031450.00-0.424-0.2640.019
put32.000.104.904.922.2461400.00-0.453-0.2740.019
put33.000.405.003.801.87327.000.00-0.596-0.1340.019
put34.001.005.5010.401.83914.000.00-0.632-0.1350.018
put35.002.006.507.651.99949.000.00-0.656-0.1470.018
put36.002.657.5011.602.14752.000.00-0.675-0.1570.018
put37.003.708.406.552.28613.000.00-0.691-0.1660.017
put38.004.709.506.922.41728.000.00-0.704-0.1740.017
put39.005.7010.5010.202.5411.000.00-0.715-0.1810.017
put40.006.7011.5010.502.6554.000.00-0.725-0.1880.016
put41.007.7012.5010.602.7700.000.00-0.733-0.1940.016
put42.008.6013.5010.852.8770.000.00-0.741-0.1990.016
put43.009.6014.5011.502.9800.000.00-0.747-0.2050.016
put44.0010.6015.5012.403.0780.000.00-0.754-0.2100.015
put45.0011.6016.5010.103.17311.000.00-0.859-0.1120.011
put46.0012.6017.5012.803.2640.000.00-0.863-0.1140.011
put47.0013.8018.5010.183.35210.000.00-0.866-0.1160.011
put48.0014.6019.5011.043.4378.000.00-0.869-0.1180.010
put49.0015.6020.5011.853.5195.000.00-0.872-0.1200.010
put50.0016.6021.500.003.5980.000.00-0.875-0.1210.010
put55.0021.6026.500.003.9620.000.00-0.885-0.1290.009
put60.0026.6031.500.004.2790.000.00-0.893-0.1350.009
put65.0031.6036.500.004.5620.000.00-0.899-0.1400.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-07SCHEDULE 13G/ASEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-158-KCurrent report2026-07-10SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-268-KCurrent report2026-06-25SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200121.21K1
2025-11001.18M1

Institutional holders

Manager% owned
WELLINGTON MANAGEMENT GROUP LLP12.16%
FMR LLC11.00%
BlackRock, Inc.8.92%
Kynam Capital Management, LP6.78%
PRICE T ROWE ASSOCIATES INC /MD/5.97%
STATE STREET CORP4.97%
VANGUARD CAPITAL MANAGEMENT LLC4.41%
Deep Track Capital, LP3.74%
Logos Global Management LP2.68%
GEODE CAPITAL MANAGEMENT, LLC2.61%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND4.82%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
iShares Russell 2000 ETF2.59%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.58%
VANGUARD EXPLORER FUND1.84%
T. Rowe Price New Horizons Fund, Inc.1.60%
Eventide Healthcare & Life Sciences Fund1.32%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.24%
VANGUARD EXTENDED MARKET INDEX FUND1.14%
Fidelity Small Cap Index Fund1.09%

OakChart. CLDX. Cached 15 minutes.